| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-77077SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | MAB3585-SP | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-56160SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-87128-25ul | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-73911 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP3-15118-25ul | |||
| Azide and BSA Free | NBP3-44182 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP3-21190-25ul | |||
| Azide and BSA Free | NBP3-44145 | |||
![Immunohistochemistry: RIPK1/RIP1 Antibody - BSA Free [NBP1-77077] - Immunohistochemistry of RIPK1/RIP1 in mouse kidney tissue with RIPK1/RIP1 antibody at 2.5 ug/mL.](http://images.novusbio.com/fullsize/nbp1-77077_rabbit-polyclonal-ripk1-rip1-antibody-271120242045651.jpg "Immunohistochemistry: RIPK1/RIP1 Antibody - BSA Free [NBP1-77077] - Immunohistochemistry of RIPK1/RIP1 in mouse kidney tissue with RIPK1/RIP1 antibody at 2.5 ug/mL.")
![Immunohistochemistry: RIPK1/RIP1 Antibody - BSA Free [NBP1-77077] - Immunohistochemistry of RIPK1/RIP1 in mouse kidney tissue with RIPK1/RIP1 antibody at 2.5 ug/ml.](http://images.novusbio.com/fullsize/nbp1-77077_rabbit-polyclonal-ripk1-rip1-antibody-2711202420272453.gif)
![<b>Biological Strategies Validation. </b>Western Blot: RIPK1/RIP1 Antibody [NBP1-77077] - At 6 h after CCI, RIP1 protein levels in the cortex detected by western blotting were decreased in Nec-1 and melatonin pretreatment groups, but there was no change in the Z-VAD pretreatment group. Values are represented as means +/- SEM (n = 3). B-actin was used as a control in western blot assays. All data were analyzed by one way ANOVA plus Tukey's test. *P < 0.05 and **P < 0.01 vs. CCI group. Image collected and cropped by CiteAb from the following publication (//www.frontiersin.org/article/10.3389/fnmol.2019.00222/full) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/RIPK1-RIP1-Antibody-Western-Blot-NBP1-77077-img0005.jpg)
![Immunohistochemistry: RIPK1/RIP1 Antibody [NBP1-77077] - Traumatic brain injury (TBI) tissues show increased necroptosis compared with normal brain tissues (NBTs). The expression of RIP1 was tested in NBT and TBI tissues from Jiangsu Province Hospital by immunohistochemistry. Image collected and cropped by CiteAb from the following publication (//www.frontiersin.org/article/10.3389/fnmol.2019.00222/full) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/RIPK1-RIP1-Antibody-Immunohistochemistry-NBP1-77077-img0007.jpg)
![Western Blot: RIPK1/RIP1 Antibody [NBP1-77077] - Rat kidney tissue lysate with RIPK1 antibody at 1 ug/mL.](http://images.novusbio.com/fullsize/RIPK1-RIP1-Antibody-Western-Blot-NBP1-77077-img0001.jpg)
![Western Blot: RIPK1/RIP1 Antibody - BSA Free [NBP1-77077] - Traumatic brain injury (TBI) tissues show increased necroptosis compared with normal brain tissues (NBTs). (A) The protein expressions of receptor-interacting protein 1 (RIP1), RIP3 & mixed lineage kinase domain-like protein (MLKL) were analyzed in human NBT (n = 4) & TBI tissues (n = 9) via western blotting. beta -actin was used as a control. (B–D) Protein expression of RIP1, RIP3 & MLKL was analyzed by statistical. (E) The expressions of RIP1, RIP3 & MLKL were tested in NBT & TBI tissues from Jiangsu Province Hospital by immunohistochemistry. (F) Electron microscopy was used to examine human normal brain & TBI tissues. Intact cell membrane (violet arrow) is labeled in NBT. Complete & continuous nuclear membrane (black arrow), swollen mitochondria (green arrow) & vacuoles (red arrow) are labeled in TBI tissues. All data were analyzed by one way analysis of variance (ANOVA) plus Tukey’s test. **P < 0.01 vs. NBT group. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31607859), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-77077_rabbit-polyclonal-ripk1-rip1-antibody-310202416171410.jpg)
![Immunohistochemistry: RIPK1/RIP1 Antibody - BSA Free [NBP1-77077] - Effect of Nec-1, Z-VAD & melatonin on necroptosis. (A) At 6 h after CCI, RIP1, RIP3 & MLKL protein levels in the cortex detected by western blotting were decreased in Nec-1 & melatonin pretreatment groups, but there was no change in the Z-VAD pretreatment group. (B–D) Protein expression of RIP1, RIP3 & MLKL was analyzed by statistical. (E) Immunohistochemistry assays examined the effect of Nec-1, Z-VAD & melatonin on cortex RIP1, RIP3 & MLKL, respectively. (F) At 6 h after CCI, RIP1, RIP3 & MLKL protein levels in the hippocampus CA1 detected by western blotting were decreased in the Nec-1 & melatonin pretreatment groups, but not the Z-VAD pretreatment group. (G–I) Protein expression of RIP1, RIP3 & MLKL was analyzed by statistical. (J) Immunohistochemistry assays examined the effect of Nec-1, Z-VAD & melatonin on RIP1, RIP3 & MLKL in hippocampus CA1, respectively. (K) TdT-mediated dUTP Nick-End Labeling (TUNEL; green) & cleaved caspase-3 (red) dual immunofluorescent labeling was used & were analyzed by statistical (L,M) in the five groups. Values are represented as means ± SEM (n = 3). beta -actin was used as a control in western blot assays. All data were analyzed by one way ANOVA plus Tukey’s test. *P < 0.05 & **P < 0.01 vs. CCI group. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31607859), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-77077_rabbit-polyclonal-ripk1-rip1-antibody-31020241616014.jpg)
![Western Blot: RIPK1/RIP1 Antibody - BSA Free [NBP1-77077] - Tissues were obtained to perform western blot assays. (A) Location of collected tissues was labeled. Collected cortical tissues & hippocampus CA1 were marked by white & yellow frame, respectively. RIP1, RIP3 & MLKL in the (B) cortex & (C) hippocampus CA1 were examined via western blot from 0 h to 48 h after controlled cortical impact (CCI). Protein expression of RIP1, RIP3 & MLKL in the (D–F) cortex & (G–I) hippocampus CA1 from 0 h to 48 h after CCI was analyzed by statistical. Values are represented as means ± SEM (n = 3–4). (J) Cleaved caspase-3 was detected in cortex & hippocampus CA1 via western blotting from 0 h to 48 h after CCI. (K,L) Protein expression of cleaved caspase-3 in the cortex & hippocampus CA1 from 0 h to 48 h after CCI was measured. Values are represented as means ± SEM (n = 4–5). (M) Cleaved caspase-8 was detected in cortex & hippocampus CA1 via western blotting from 0 h to 48 h after CCI. (N,O) Protein expression of cleaved caspase-8 in the cortex & hippocampus CA1 from 0 h to 48 h after CCI was analyzed. Values are represented as means ± SEM (n = 4–5). beta -actin was used as a control in western blot assays. All data were analyzed by one way ANOVA plus Tukey’s test. *P < 0.05 & **P < 0.01 vs. sham group. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31607859), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-77077_rabbit-polyclonal-ripk1-rip1-antibody-31020241618915.jpg)
![Immunohistochemistry: RIPK1/RIP1 Antibody - BSA Free [NBP1-77077] - Traumatic brain injury (TBI) tissues show increased necroptosis compared with normal brain tissues (NBTs). (A) The protein expressions of receptor-interacting protein 1 (RIP1), RIP3 & mixed lineage kinase domain-like protein (MLKL) were analyzed in human NBT (n = 4) & TBI tissues (n = 9) via western blotting. beta -actin was used as a control. (B–D) Protein expression of RIP1, RIP3 & MLKL was analyzed by statistical. (E) The expressions of RIP1, RIP3 & MLKL were tested in NBT & TBI tissues from Jiangsu Province Hospital by immunohistochemistry. (F) Electron microscopy was used to examine human normal brain & TBI tissues. Intact cell membrane (violet arrow) is labeled in NBT. Complete & continuous nuclear membrane (black arrow), swollen mitochondria (green arrow) & vacuoles (red arrow) are labeled in TBI tissues. All data were analyzed by one way analysis of variance (ANOVA) plus Tukey’s test. **P < 0.01 vs. NBT group. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31607859), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-77077_rabbit-polyclonal-ripk1-rip1-antibody-310202416175211.jpg)
![Western Blot: RIPK1/RIP1 Antibody - BSA Free [NBP1-77077] - Effect of Nec-1, Z-VAD & melatonin on necroptosis. (A) At 6 h after CCI, RIP1, RIP3 & MLKL protein levels in the cortex detected by western blotting were decreased in Nec-1 & melatonin pretreatment groups, but there was no change in the Z-VAD pretreatment group. (B–D) Protein expression of RIP1, RIP3 & MLKL was analyzed by statistical. (E) Immunohistochemistry assays examined the effect of Nec-1, Z-VAD & melatonin on cortex RIP1, RIP3 & MLKL, respectively. (F) At 6 h after CCI, RIP1, RIP3 & MLKL protein levels in the hippocampus CA1 detected by western blotting were decreased in the Nec-1 & melatonin pretreatment groups, but not the Z-VAD pretreatment group. (G–I) Protein expression of RIP1, RIP3 & MLKL was analyzed by statistical. (J) Immunohistochemistry assays examined the effect of Nec-1, Z-VAD & melatonin on RIP1, RIP3 & MLKL in hippocampus CA1, respectively. (K) TdT-mediated dUTP Nick-End Labeling (TUNEL; green) & cleaved caspase-3 (red) dual immunofluorescent labeling was used & were analyzed by statistical (L,M) in the five groups. Values are represented as means ± SEM (n = 3). beta -actin was used as a control in western blot assays. All data were analyzed by one way ANOVA plus Tukey’s test. *P < 0.05 & **P < 0.01 vs. CCI group. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31607859), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-77077_rabbit-polyclonal-ripk1-rip1-antibody-310202416163731.jpg)
![Western Blot: RIPK1/RIP1 Antibody - BSA Free [NBP1-77077] - Tissues were obtained to perform western blot assays. (A) Location of collected tissues was labeled. Collected cortical tissues & hippocampus CA1 were marked by white & yellow frame, respectively. RIP1, RIP3 & MLKL in the (B) cortex & (C) hippocampus CA1 were examined via western blot from 0 h to 48 h after controlled cortical impact (CCI). Protein expression of RIP1, RIP3 & MLKL in the (D–F) cortex & (G–I) hippocampus CA1 from 0 h to 48 h after CCI was analyzed by statistical. Values are represented as means ± SEM (n = 3–4). (J) Cleaved caspase-3 was detected in cortex & hippocampus CA1 via western blotting from 0 h to 48 h after CCI. (K,L) Protein expression of cleaved caspase-3 in the cortex & hippocampus CA1 from 0 h to 48 h after CCI was measured. Values are represented as means ± SEM (n = 4–5). (M) Cleaved caspase-8 was detected in cortex & hippocampus CA1 via western blotting from 0 h to 48 h after CCI. (N,O) Protein expression of cleaved caspase-8 in the cortex & hippocampus CA1 from 0 h to 48 h after CCI was analyzed. Values are represented as means ± SEM (n = 4–5). beta -actin was used as a control in western blot assays. All data were analyzed by one way ANOVA plus Tukey’s test. *P < 0.05 & **P < 0.01 vs. sham group. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31607859), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-77077_rabbit-polyclonal-ripk1-rip1-antibody-310202416163751.jpg)
![Immunohistochemistry: RIPK1/RIP1 Antibody - BSA Free [NBP1-77077] - Effect of Nec-1, Z-VAD & melatonin on necroptosis. (A) At 6 h after CCI, RIP1, RIP3 & MLKL protein levels in the cortex detected by western blotting were decreased in Nec-1 & melatonin pretreatment groups, but there was no change in the Z-VAD pretreatment group. (B–D) Protein expression of RIP1, RIP3 & MLKL was analyzed by statistical. (E) Immunohistochemistry assays examined the effect of Nec-1, Z-VAD & melatonin on cortex RIP1, RIP3 & MLKL, respectively. (F) At 6 h after CCI, RIP1, RIP3 & MLKL protein levels in the hippocampus CA1 detected by western blotting were decreased in the Nec-1 & melatonin pretreatment groups, but not the Z-VAD pretreatment group. (G–I) Protein expression of RIP1, RIP3 & MLKL was analyzed by statistical. (J) Immunohistochemistry assays examined the effect of Nec-1, Z-VAD & melatonin on RIP1, RIP3 & MLKL in hippocampus CA1, respectively. (K) TdT-mediated dUTP Nick-End Labeling (TUNEL; green) & cleaved caspase-3 (red) dual immunofluorescent labeling was used & were analyzed by statistical (L,M) in the five groups. Values are represented as means ± SEM (n = 3). beta -actin was used as a control in western blot assays. All data were analyzed by one way ANOVA plus Tukey’s test. *P < 0.05 & **P < 0.01 vs. CCI group. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31607859), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-77077_rabbit-polyclonal-ripk1-rip1-antibody-310202416163761.jpg)
![Immunocytochemistry/ Immunofluorescence: RIPK1/RIP1 Antibody - BSA Free [NBP1-77077] - Immunofluorescence of RIPK1/RIP1 in Mouse Kidney cells with RIPK1/RIP1 antibody at 20 ug/mL.](http://images.novusbio.com/fullsize/nbp1-77077_rabbit-polyclonal-ripk1-rip1-antibody-2711202419172268.jpg)
![Immunohistochemistry-Paraffin: RIPK1/RIP1 Antibody [NB100-56160] - Analysis of tonsil using this antibody at 1:2000 in (A) low magnification overview of a secondary follicle. (A1) and (A2), sucessively higher magnifications of the germinal center from (A). Hematoxylin-eosin counterstain.](http://images.novusbio.com/fullsize/RIPK1-RIP1-Antibody-Immunohistochemistry-Paraffin-NB100-56160-img0005.jpg "Immunohistochemistry-Paraffin: RIPK1/RIP1 Antibody [NB100-56160] - Analysis of tonsil using this antibody at 1:2000 in (A) low magnification overview of a secondary follicle. (A1) and (A2), sucessively higher magnifications of the germinal center from (A). Hematoxylin-eosin counterstain.")
![Immunohistochemistry-Paraffin: RIPK1/RIP1 Antibody [NB100-56160] - Tissue sections using NB100-56160 at 1:2000 of (A) normal human breast and (B) normal human colon. Plasma cells in the lamina propia of the colon are stained. Hematoxylin-eosin counterstain.](http://images.novusbio.com/fullsize/RIPK1-RIP1-Antibody-Immunohistochemistry-NB100-56160-img0004.jpg)
![Western Blot: RIPK1/RIP1 Antibody [NBP1-87128] - Analysis in human cell line HDLM-2.](http://images.novusbio.com/fullsize/RIPK1-RIP1-Antibody-Western-Blot-NBP1-87128-img0017.jpg "Western Blot: RIPK1/RIP1 Antibody [NBP1-87128] - Analysis in human cell line HDLM-2.")
![Immunocytochemistry/Immunofluorescence: RIPK1/RIP1 Antibody [NBP1-87128] - Staining of human cell line A-431 shows localization to cytosol. Antibody staining is shown in green.](http://images.novusbio.com/fullsize/RIPK1-RIP1-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-87128-img0007.jpg)
![Immunohistochemistry-Paraffin: RIPK1/RIP1 Antibody [NBP1-87128] - Staining of human small intestine shows strong cytoplasmic positivity in glandular cells.](http://images.novusbio.com/fullsize/RIPK1-RIP1-Antibody-Immunohistochemistry-Paraffin-NBP1-87128-img0016.jpg)
![<b>Orthogonal Strategies Validation. </b>Immunohistochemistry-Paraffin: RIPK1/RIP1 Antibody [NBP1-87128] - Analysis in human small intestine and skeletal muscle tissues. Corresponding RIPK1/RIP1 RNA-seq data are presented for the same tissues.](http://images.novusbio.com/fullsize/RIPK1-RIP1-Antibody-Immunohistochemistry-Paraffin-NBP1-87128-img0012.jpg)
![Immunohistochemistry-Paraffin: RIPK1/RIP1 Antibody [NBP1-87128] - Staining of human placenta shows moderate cytoplasmic positivity in trophoblastic cells.](http://images.novusbio.com/fullsize/RIPK1-RIP1-Antibody-Immunohistochemistry-Paraffin-NBP1-87128-img0013.jpg)
![Immunohistochemistry-Paraffin: RIPK1/RIP1 Antibody [NBP1-87128] - Staining of human prostate shows moderate cytoplasmic positivity in smooth muscle cells.](http://images.novusbio.com/fullsize/RIPK1-RIP1-Antibody-Immunohistochemistry-Paraffin-NBP1-87128-img0014.jpg)
![Immunohistochemistry-Paraffin: RIPK1/RIP1 Antibody [NBP1-87128] - Staining of human skeletal muscle shows no positivity in myocytes as expected.](http://images.novusbio.com/fullsize/RIPK1-RIP1-Antibody-Immunohistochemistry-Paraffin-NBP1-87128-img0015.jpg)
![Western Blot: RIPK1/RIP1 Antibody (2D6) [NBP2-45591] - Analysis of HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY RIPK1.](http://images.novusbio.com/fullsize/RIPK1-RIP1-Antibody-2D6-Western-Blot-NBP2-45591-img0008.jpg "Western Blot: RIPK1/RIP1 Antibody (2D6) [NBP2-45591] - Analysis of HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY RIPK1.")
![Immunohistochemistry: RIPK1/RIP1 Antibody (2D6) [NBP2-45591] - Analysis of Carcinoma of Human prostate tissue.](http://images.novusbio.com/fullsize/RIPK1-RIP1-Antibody-2D6-Immunohistochemistry-NBP2-45591-img0007.jpg)
![Western Blot: RIPK1/RIP1 Antibody (2D6) [NBP2-45591] - Analysis of extracts (10ug) from 2 different cell lines COS7: monkey; MDCK: canine.](http://images.novusbio.com/fullsize/RIPK1-RIP1-Antibody-2D6-Western-Blot-NBP2-45591-img0009.jpg)
![Immunohistochemistry: RIPK1/RIP1 Antibody (2D6) [NBP2-45591] - Analysis of Adenocarcinoma of Human colon tissue.](http://images.novusbio.com/fullsize/RIPK1-RIP1-Antibody-2D6-Immunohistochemistry-NBP2-45591-img0001.jpg)
![Immunohistochemistry: RIPK1/RIP1 Antibody (2D6) [NBP2-45591] - Analysis of Adenocarcinoma of Human endometrium tissue.](http://images.novusbio.com/fullsize/RIPK1-RIP1-Antibody-2D6-Immunohistochemistry-NBP2-45591-img0002.jpg)
![Immunohistochemistry: RIPK1/RIP1 Antibody (2D6) [NBP2-45591] - Analysis of Human lymphoma tissue.](http://images.novusbio.com/fullsize/RIPK1-RIP1-Antibody-2D6-Immunohistochemistry-NBP2-45591-img0003.jpg)
![Immunohistochemistry: RIPK1/RIP1 Antibody (2D6) [NBP2-45591] - Analysis of Carcinoma of Human thyroid tissue.](http://images.novusbio.com/fullsize/RIPK1-RIP1-Antibody-2D6-Immunohistochemistry-NBP2-45591-img0004.jpg)
![Immunohistochemistry: RIPK1/RIP1 Antibody (2D6) [NBP2-45591] - Analysis of Human breast tissue.](http://images.novusbio.com/fullsize/RIPK1-RIP1-Antibody-2D6-Immunohistochemistry-NBP2-45591-img0005.jpg)
![Immunohistochemistry: RIPK1/RIP1 Antibody (2D6) [NBP2-45591] - Analysis of Human Kidney tissue.](http://images.novusbio.com/fullsize/RIPK1-RIP1-Antibody-2D6-Immunohistochemistry-NBP2-45591-img0006.jpg)
![Immunocytochemistry/Immunofluorescence: RIPK1/RIP1 Antibody (HL2250) - Azide and BSA Free [NBP3-25637] - RIP antibody [HL2250] detects RIP protein at cytoplasm by immunofluorescent analysis. Sample: HeLa cells were fixed in ice-cold MeOH for 5 min. Green: RIP stained by RIP antibody [HL2250] (NBP3-25637) diluted at 1:100. Blue: Fluoroshield with DAPI .](http://images.novusbio.com/fullsize/nbp3-25637_rabbit-ripk1-rip1-mab-hl2250-azide-and-bsa-free-2120249425413.jpg "Immunocytochemistry/Immunofluorescence: RIPK1/RIP1 Antibody (HL2250) - Azide and BSA Free [NBP3-25637] - RIP antibody [HL2250] detects RIP protein at cytoplasm by immunofluorescent analysis. Sample: HeLa cells were fixed in ice-cold MeOH for 5 min. Green: RIP stained by RIP antibody [HL2250] (NBP3-25637) diluted at 1:100. Blue: Fluoroshield with DAPI .")
![Western Blot: RIPK1/RIP1 Antibody (HL2250) - Azide and BSA Free [NBP3-25637] - Untreated (-) and treated (+) NCI-H929 whole cell extract (30 ug) were separated by 10% SDS-PAGE, and the membrane was blotted with RIP antibody [HL2250] (NBP3-25637) diluted at 1:1000. The HRP-conjugated anti-rabbit IgG antibody was used to detect the primary antibody, and the signal was developed with Trident ECL plus-Enhanced.](http://images.novusbio.com/fullsize/nbp3-25637_rabbit-ripk1-rip1-mab-hl2250-azide-and-bsa-free-212024940853.jpg)
![Western Blot: RIPK1/RIP1 Antibody (HL2250) - Azide and BSA Free [NBP3-25637] - Various whole cell extracts (30 ug) were separated by 7.5% SDS-PAGE, and the membrane was blotted with RIP antibody [HL2250] (NBP3-25637) diluted at 1:1000. The HRP-conjugated anti-rabbit IgG antibody was used to detect the primary antibody.](http://images.novusbio.com/fullsize/nbp3-25637_rabbit-ripk1-rip1-mab-hl2250-azide-and-bsa-free-2120249371596.jpg)
![Immunohistochemistry-Paraffin: RIPK1/RIP1 Antibody (HL2250) - Azide and BSA Free [NBP3-25637] - RIP antibody [HL2250] detects RIP protein at cell membrane and cytoplasm by immunohistochemical analysis. Sample: Paraffin-embedded human breast carcinoma. RIP stained by RIP antibody [HL2250] (NBP3-25637) diluted at 1:100. Antigen Retrieval: Citrate buffer, pH 6.0, 15 min](http://images.novusbio.com/fullsize/nbp3-25637_rabbit-ripk1-rip1-mab-hl2250-azide-and-bsa-free-2120249422620.jpg)
![Western Blot: RIPK1/RIP1 Antibody (C4) [NBP3-41895] - Sample: Lane1: K562 cell lysate; Lane2: A549 cell lysate; Lane3: HepG2 cell lysate; Lane4: Raji cell lysate; Lane5: Human Serum Primary Ab: 1.5ug/ml NBP3-41895; Second Ab: 0.2ug/mL HRP-Linked Caprine Anti-Mouse IgG Polyclonal Antibody](http://images.novusbio.com/fullsize/nbp3-41895_mouse-ripk1-rip1-mab-c4-612202421395381.jpg "Western Blot: RIPK1/RIP1 Antibody (C4) [NBP3-41895] - Sample: Lane1: K562 cell lysate; Lane2: A549 cell lysate; Lane3: HepG2 cell lysate; Lane4: Raji cell lysate; Lane5: Human Serum Primary Ab: 1.5ug/ml NBP3-41895; Second Ab: 0.2ug/mL HRP-Linked Caprine Anti-Mouse IgG Polyclonal Antibody")
![Immunohistochemistry-Paraffin: RIPK1/RIP1 Antibody (C4) [NBP3-41895] - DAB staining on IHC-P; Sample: Human Kidney Tissue; Primary Ab: 30ug/ml NBP3-41895; Second Ab: 2ug/mLÂ HRP-Linked Caprine Anti-Mouse IgG Polyclonal Antibody](http://images.novusbio.com/fullsize/nbp3-41895_mouse-ripk1-rip1-mab-c4-612202421351228.jpg)
![Immunohistochemistry-Paraffin: RIPK1/RIP1 Antibody [NBP2-20166] - RIPK1/RIP1 antibody [C1C3] detects RIPK1/RIP1 protein at cytoplasm by immunohistochemical analysis.Sample: Paraffin-embedded human cervical carcinoma.RIPK1/RIP1 stained by RIPK1/RIP1 antibody [C1C3] (NBP2-20166) diluted at 1:500.Antigen Retrieval: Citrate buffer, pH 6.0, 15 min](http://images.novusbio.com/fullsize/nbp2-20166_rabbit-polyclonal-ripk1-rip1-antibody-910202420131299.jpg "Immunohistochemistry-Paraffin: RIPK1/RIP1 Antibody [NBP2-20166] - RIPK1/RIP1 antibody [C1C3] detects RIPK1/RIP1 protein at cytoplasm by immunohistochemical analysis.Sample: Paraffin-embedded human cervical carcinoma.RIPK1/RIP1 stained by RIPK1/RIP1 antibody [C1C3] (NBP2-20166) diluted at 1:500.Antigen Retrieval: Citrate buffer, pH 6.0, 15 min")
![Western Blot: RIPK1/RIP1 Antibody [NBP2-20166] - Whole cell extract (30 ug) was separated by 7.5% SDS-PAGE, and the membrane was blotted with RIPK1/RIP1 antibody [C1C3] (NBP2-20166) diluted at 1:1000. The HRP-conjugated anti-rabbit IgG antibody was used to detect the primary antibody.](http://images.novusbio.com/fullsize/nbp2-20166_rabbit-polyclonal-ripk1-rip1-antibody-910202420131265.jpg)
![Western Blot: RIPK1/RIP1 Antibody [NBP2-20166] - Whole cell extract (30 ug) was separated by 7.5% SDS-PAGE, and the membrane was blotted with RIPK1/RIP1 antibody [C1C3] (NBP2-20166) diluted at 1:1000. The HRP-conjugated anti-rabbit IgG antibody was used to detect the primary antibody.](http://images.novusbio.com/fullsize/nbp2-20166_rabbit-polyclonal-ripk1-rip1-antibody-91020242014697.jpg)
![Western Blot: RIPK1/RIP1 Antibody (2V4N8) [NBP3-15786] - Western blot analysis of extracts of various cell lines, using RIPK1/RIP1 antibody (NBP3-15786) at 1:1000 dilution. Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) at 1:10000 dilution. Lysates/proteins: 25ug per lane. Blocking buffer: 3% nonfat dry milk in TBST. Detection: ECL Basic Kit. Exposure time: 3min.](http://images.novusbio.com/fullsize/RIPK1-RIP1-Antibody-2V4N8-Western-Blot-NBP3-15786-img0001.jpg "Western Blot: RIPK1/RIP1 Antibody (2V4N8) [NBP3-15786] - Western blot analysis of extracts of various cell lines, using RIPK1/RIP1 antibody (NBP3-15786) at 1:1000 dilution. Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) at 1:10000 dilution. Lysates/proteins: 25ug per lane. Blocking buffer: 3% nonfat dry milk in TBST. Detection: ECL Basic Kit. Exposure time: 3min.")
![Immunoprecipitation: RIPK1/RIP1 Antibody (2V4N8) [NBP3-15786] - Immunoprecipitation analysis of 300ug extracts of HeLa cells using 3ug RIPK1/RIP1 antibody (NBP3-15786). Western blot was performed from the immunoprecipitate using RIPK1/RIP1 antibody (NBP3-15786) at a dilition of 1:500.](http://images.novusbio.com/fullsize/RIPK1-RIP1-Antibody-2V4N8-Immunoprecipitation-NBP3-15786-img0002.jpg)
![Western Blot: RIPK1/RIP1 Antibody (CL11368) [NBP3-15118] - Analysis in human cell line HDLM-2.](http://images.novusbio.com/fullsize/RIPK1-RIP1-Antibody-CL11368-Western-Blot-NBP3-15118-img0001.jpg "Western Blot: RIPK1/RIP1 Antibody (CL11368) [NBP3-15118] - Analysis in human cell line HDLM-2.")
